BACKGROUND The EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High-Risk registry and REALISM
Globally, the percutaneous mitral valve edge-toedge repair device (MitraClip, Abbott Vascular, Santa Clara, California) has been used in more than 10,000 patients to mechanically reduce MR without the incisions and cardiopulmonary bypass needed for MV surgery. Although initial MV trials included patients with low to medium surgical risk, current usage and evidence suggest that a primary role for the MV device may be to treat symptomatic MR in patients who are either unsuitable or at high risk for MV surgery (7) . patients with grades 3 to 4þ MR for whom surgical risk for perioperative mortality was $12%, as estimated using the STS calculator (9) or by a surgeon coinvestigator based on pre-specified criteria (described in the Methods section). The inclusion/exclusion criteria of these 2 registries were essentially the same, allowing data from both of these studies to be pooled and analyzed together.
The EVEREST II (Endovascular Valve
The current investigation is a prospective, multicenter evaluation of the safety and effectiveness of the MV device in patients from both of the EVEREST II high-risk studies who had completed 12 months of follow-up.
METHODS P A T I E N T S E L E C T I O N .
For inclusion in these studies, patients had to be symptomatic with grades 3 to 4þ MR and have valve morphology meeting the criteria necessary for MV device placement (10) .
Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) screening tests were used to establish protocol-based eligibility for the procedure (11) (12) (13) (14) . MR severity and jet origin were assessed by TTE. The primary regurgitant jet had to originate from leaflet malcoaptation at the A2/P2 region (10) . TEE was used to assess MV leaflet anatomy for 30-day mortality was 7.6%, which was lower than the predicted STS mortality. Additional 30-day major adverse event rates were low ( Table 2 ). The most common adverse event was transfusion of at least 2 U of blood occurring in 13.4% of patients, the majority of which was given for bleeding related to access during the procedure. Additional transfusions were given prophylactically or due to anemia.
Of the 9 strokes that occurred within 30 days, 7
were ischemic and 2 were hemorrhagic. Strokes occurred in patients with a median age of 78 years Few additional complications occurred between 30 days and 12 months. The 1-year stroke rate was 3.4%, which was expected considering that 69% of the population had a history of atrial fibrillation.
Other event rates remained low, with the most common event being transfusion of at least 2 U of blood ( Table 2) . Transfusions administered beyond 30 days were most often for bleeding unrelated to the MitraClip procedure or for anemia, with only 1 transfusion administered after 30 days for access site bleeding.
D E V I C E C O M P L I C A T I O N S .
Complications specifically related to the device occurred at a low rate ( 
E F F E C T I V E N E S S A T 1 2 M O N T H S .
Effectiveness of the procedure, defined as MR reduction to grade #2þ, is presented in Table 5 ). Table 1) . Safety and effectiveness outcomes also were examined by MR cause ( Table 6 ). DMR patients were older, on average, than FMR patients (by 9 years), but the 2 groups were otherwise comparable. Safety outcomes were similar between the 2 groups, and both of the groups experienced improvements in effectiveness measures. Change in mitral regurgitation severity is shown at baseline, discharge, and 12 months, using paired analysis. Whether MV device imparts a survival benefit in this patient group is less clear from these data and merits further study. Several studies have suggested that the device does, on average, improve HF symptoms and quality of life in selected patients (11, 18) . A survival 
DISCUSSION

